Target Price | $45.90 |
Price | $47.60 |
Deviation |
3.57%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Supernus Pharmaceuticals, Inc. 2026 .
The average Supernus Pharmaceuticals, Inc. target price is $45.90.
This is
3.57%
register free of charge
$48.30
1.47%
register free of charge
$40.40
15.13%
register free of charge
|
|
A rating was issued by 11 analysts: 8 Analysts recommend Supernus Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Supernus Pharmaceuticals, Inc. stock has an average upside potential 2026 of
3.57%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 661.82 | 703.41 |
8.94% | 6.28% | |
EBITDA Margin | 25.47% | 13.97% |
58.99% | 45.14% | |
Net Margin | 11.16% | 18.09% |
5,037.06% | 62.07% |
7 Analysts have issued a sales forecast Supernus Pharmaceuticals, Inc. 2025 . The average Supernus Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Supernus Pharmaceuticals, Inc. EBITDA forecast 2025. The average Supernus Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Supernus Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Supernus Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 1.32 | 2.27 |
6,500.00% | 71.97% | |
P/E | 20.99 | |
EV/Sales | 3.05 |
7 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast for earnings per share. The average Supernus Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Supernus Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 19 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Sep 11 2024 |
Analyst Rating | Date |
---|---|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 29 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 26 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 19 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Sep 11 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.